Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib versus placebo after prior sorafenib in advanced hepatocellular carcinoma
NL-OMON47199Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Cabozantinib with Placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2014; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON47199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47199.